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Synthesis of AG10 analogs and optimization of the structure of TTR Ligands for Halflife Enhancement (TLHE) for peptides

Abstract

by
Raghavendra Jampala

UNIVERSITY OF THE PACIFIC
2017

The misassembly of soluble proteins into toxic aggregates, including amyloid fibrils,
underlies a large number of human degenerative diseases. Like cardiac amyloidosis, which is
most commonly, caused by aggregation of Immunoglobulin (Ig) light chains or transthyretin
(TTR) in the cardiac muscle, represent an important and often underdiagnosed cause of heart
failure. TTR-mediated amyloid cardiomyopathies are chronic and progressive conditions that lead
to arrhythmias, biventricular heart failure, and death. As no Food and Drug Administrationapproved drugs are currently available for treatment of these diseases, the development of
therapeutic agents that prevent TTR-mediated cardiotoxicity is desired. AG10 is a potent and
selective kinetic stabilizer of TTR. AG10 prevents dissociation of TTR in serum samples
obtained from patients with amyloid cardiomyopathy. The oral bioavailability and selectivity of
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AG10, makes it a very promising candidate to treat TTR amyloid cardiomyopathy. Understanding
the reason behind the potency of AG10 would be beneficial for designing stabilizers for other
amyloid diseases. This would be possible by designing and synthesizing structural analogues of
AG10. Here we report the synthesis, characterization and analysis of AG10 analogs and compare
the in vitro activities of the synthesized analogs.
The tremendous therapeutic potential of peptides has not been fulfilled and potential
peptide therapies that have failed far outnumber the successes so far. A major challenge impeding
the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to
short in vivo half-life resulting from inactivation by serum proteases and rapid elimination by
kidneys. Extending the in vivo half-life of peptides is clearly desirable in order for their
therapeutic potential to be realized, without the need for high doses and/or frequent
administration. Covalent conjugation of peptides to macromolecules (e.g. polyethylene glycol or
serum proteins such albumin) has been the mainstay approach for enhancing the in vivo half-life
of peptides. However, the steric hindrance and immunogenicity of these large macromolecules
often compromises the in vivo efficacy of the peptides. Recently, our laboratory established the
first successful reversible method of extending the half-life of peptides using serum protein
Transthyretin (TTR). The approach involved the use of a TTR Ligand for Half-life Extension
((TLHE-1) which binds to TTR with high specificity and affinity. We have shown that our
technology extends the half-life of multiple peptides without seriously affecting their activity.
Our main objective here is to modify the structure of the TLHE1 using linkers with different
length and composition to optimize its affinity and selectivity for TTR in human serum.
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Chapter 1.General Introduction
1.1 Transthyretin
Transthyretin (TTR) is a 55kDa homo-tetrameric protein present in both plasma and
cerebrospinal fluid. TTR is synthesized by the liver and secreted into the blood, where it acts as a
backup carrier for thyroxine (T4) and primary carrier of holo retinol-binding protein (RBP). The
crystalline structure of transthyretin is showed in (Figure.1) [1, 2, 3]. TTR invokes great scientific and
medical interest as it is one of more than 30 proteins whose aggregation could cause disease by a
gaining toxic function mechanism leading to amyloid fibril formation, in nervous system, soft tissue,
and solid organs [3]. TTR aggregation, dissociation, and misfolding are known to be primarily
responsible for several amyloid-related diseases like familial amyloid polyneuropathy (FAP), familial
amyloid cardiomyopathy (FAC) and senile systemic amyloidosis (SSA).

Figure.1: Crystal structure image of Transtyretin
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TTR in plasma is primarily synthesized in the liver, while TTR in the brain is synthesized
by choroid plexus. TTR is also synthesized at lower amounts in several other tissues such as
retinal pigment epithelium of the eye, islets of Langerhans of the pancreas, intestine and
meninges [4]. TTR present in blood is produced and secreted by the hepatocytes in the liver.
Normal TTR concentrations in healthy adults range between 0.2 – 0.4 mg/mL (3.5 – 7 µM) [5].
When the liver is participating in acute phase response to injury, malnutrition, or chronic
inflammation there is a significant decrease in plasma or blood TTR levels. Hence, TTR levels
are used as a marker for nutritional and inflammatory status in the clinic especially in settings
where it is difficult to obtain a more detailed and comprehensive nutritional assessment such as
evaluation of albumin, α1-acid glycoprotein, and C-reactive protein [6].

1.2 Structure of TTR
Human TTR is composed of four identical 127 amino acid residue subunits (~14 kDa)
that form an extensive β-sheet structure [7]. The four identical subunits (or monomers) of TTR
assemble to form an internal channel at the weaker dimer–dimer interface where two T4
molecules could bind on the resulting tetramer [4, 7]. Recent studies have revealed that due to the
presence of two other T4 transport proteins in blood these T4 binding sites remain largely
unoccupied in humans (<1 % T4 bound) and among those occupied, only one site is filled as there
is negative cooperativity in the binding of the second T 4 [8, 9]. In addition to thyroid hormones
(T4) and its metabolites, several other pharmacologic agents and natural products, such as plant
flavonoids, nonsteroidal analgesic drugs, and inotropic bipyridines, are strong competitors for T 4
binding to TTR and have binding affinities greater than T4 [4, 10].
The structure of human wild-type TTR (WT-TTR) was one of the first proteins to be
determined by X-ray crystallography [2]. Currently (as of June 2017), there are about 267
reported TTR crystal structures and their variants listed in the Protein Data Bank (PDB,
www.rcsb.org) representing five species of protein (human, rat, mouse, chicken, and fish).
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Studies have shown that the amino acid sequence of human WT- TTR is about 85 % identical to
that from various other species [11].

1.3 Function and clinical importance of TTR
The most important role of TTR is the transport of T 4 and retinol. However, recent
studies have indicated that TTR may also play an important physiological role in proteolysis and
transport of other miscellaneous ligands [12]. TTR is not the primary transporter of T 4 (less than
1 % bound), due to the presence of two other T 4 transport proteins in blood, thyroxine-binding
globulin (TBG) and albumin, the T4 binding sites remain largely unoccupied in humans [13, 14].
However, in CSF, TTR is a major transporter of T4 in both humans and rats. Interestingly, unlike
in human plasma, TTR is the major transporter of T 4 in rats. As there is negative cooperativity
between the two T4 binding pockets, each TTR tetramer carries no more than one T 4 molecule at
a time [15]. Retinol or vitamin A circulates in blood, bound to retinol binding protein (holo-RBP)
which is found in complex with TTR. Evolution has proposed this association to facilitate RBP
release from its site of synthesis in the endoplasmic reticulum and to prevent renal filtration of
RBP [16, 17]. The presence of retinol bound to RBP is essential for the formation of a stable
complex with TTR [18]. Structural studies revealed that the RBP binding site on TTR is
orthogonal to TTR T4-binding pockets (Figure.1.1). In plasma, RBP binds to TTR in 1:1 molar
ratio due to limited concentration of RBP available. Recently, TTR has shown to have protective
effect against amyloid beta (Aβ) deposition in Alzheimer’s disease (AD). Studies have shown
that TTR could bind and cleave soluble Aβ and prevents the Aβ amyloid fibril formation in vitro
[19]. TTR cleaves Aβ in multiple positions generating shorter Aβ peptides displaying lower
amyloidogenic potential. Also, TTR was able to degrade aggregated forms of Aβ and may
contribute to maintenance of normal Aβ levels in the brain.
Kinetic stabilizers of the native tetrameric structure of TTR by interallelic trans
suppression in compound heterozygote patients, that carry both the destabilizing V30M as well as
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a second, disease suppressing mutation (T119M) [20], or by a small molecule which occupies the
T4-binding sites, raises a dissociative transition state energy and prevents amyloidosis (Figure
1.2). Recently, clinical trial on tafamidis a TTR kinetic stabilizer, indicates that it slows the
progression of early stage neuropathy in FAP patients [21]. Currently, they are no FDA-approved
drugs for the treatment or prevention of FAC or SSA. As a result, therapy for most patients is
confined to symptomatic reliefs. The treatment of choice to remove the mutated protein is by
replacing the liver for hereditary TTR amyloidosis. Combined liver and heart transplantation is
performed as a palliative measure for a subset of FAC patients [22]. The risk and cost of organ
transplantation is substantial and transplant patient requires lifelong use of immune-suppressive
drugs leading to morbidity. Due to these circumstances; there is an urgent need for a
pharmacologic treatment of TTR cardiomyopathy.
We used high-throughput screening (HTS) for TTR ligands, which enabled the
identification of a variety of potent and structurally very different TTR kinetic stabilizers. Our lab
used the previous compounds as a starting point for structure-activity relationship studies and
synthesized a series of analogs, one of which the best hits from HTS named AG10 [3] is a highly
effective and selective stabilizer of TTR. Understanding the reason behind the potency of AG10
would be beneficial for designing stabilizers for other amyloid diseases. This would be possible
by designing and synthesizing structural analogues of AG10. Here we report the synthesis of
AG10 analogs (Figure.2) and the evaluation of their in vitro activity in stabilizing TTR in
comparison to tafamidis and AG10.
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Figure.1.1: TTR bound to T4 and holo-Retinol-binding protein (holo-RBP).
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Figure.1.2: The TTR amyloidogenesis cascade and a table summarizing TTR-mediated amyloidoses. TTR
amyloidoses require rate-limiting tetramer dissociation to dimers, followed by dissociation into monomers
before partial unfolding of monomers yields the aggregation-prone amyloidogenic intermediate. The
amyloidogenic intermediate can misassemble to form a variety of toxic aggregates, including amyloid
fibrils. Disease-associated destabilizing mutations can kinetically or thermodynamically destabilize TTR.
Kinetic stabilization can be achieved through trans-allelic suppression with the kinetically stabilized
T119M-TTR, binding to T4 or other small molecules (Lower Left).
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Figure.1.3: Crystal structures of TTR ligand complexes. (A) Quaternary structure of 1 bound to WTTTR shown as a ribbon representation with monomers colored individually. (B) 1 in complex with WTTTR (3P3T). (C) AG10 in complex with V122I-TTR showing the introduced carboxylate making
electrostatic salt bridge interactions with Lys15 and Lys15'. Close-up views of one of the two identical T 4binding sites in a ribbon depicted tetramer colored by chain. A “Connolly” molecular surface was applied
to residues within 10 Å of ligand in the T 4-binding pocket hydrophobic (grey), polar (purple). The
innermost halogen binding pockets (HBPs) 3 and 3′ are composed of the methyl and methylene groups of
S117/117′, T119/119′, and L110/110′. HBPs 2 and 2′ are made up by the side chains of L110/110′,
A109/109′, K15/15′, and L17/17′. The outermost HBPs 1 and 1′ are lined by the methyl and methylene
groups of K15/15′, A108/108′, and T106/106′. Hydrogen bonds shown in light blue dashed lines, with the
atomic distances labeled in Å.
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Chapter 2. Synthesis of AG10 Analogs

2.1 Methods and Materials
Pre-albumin from human plasma (human TTR) was purchased from Sigma, probe was
synthesized in lab. All other starting materials for the synthesis of AG10 analogs were purchased from
Alfa Aesar and Accela. The solvents used were ACS grade purchased from Fisher Scientific, and reagents
were purchased from Aldrich and Acros, and used without further purifications. Reactions were
monitored using thin-layer chromatography (TLC) carried out on 0.2mm POLYGRAM® SIL silica gel
plates with fluorescent indicator UV254 using UV light as a visualizer. For purification normal phase
flash column chromatography was carried out using Davisil® silica gel (100-200 mesh, Fisher Scientific),
High-resolution mass spectra (HRMS) were determined by JEOL AccuTOF DART using helium as an
ionization gas and HPLC analysis was performed on a Waters™ Alliance 2790 system attached to
Waters™ 2990 PDA detector operating between the UV ranges of 200 – 400 nm. A empower 2.0 data
acquisition system was used for quantification purposes. A Waters™ XBridge C18 column with L1
packing (4.6 X 150 mm, 5μm) was used at ambient temperature. The UV absorbance was recorded at
280 nm and 254 nm.
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AG10

AG10 Analog 1

AG10 Analogue 2

Figure.2: Structure of AG10, AG10 Analog 1 & AG10 Analog 2 showing difference in the position of
fluorine.

2.2 Chemical Synthesis of AG10
The chemical synthesis of AG10 is very similar to what was reported earlier for AG10
[3]. The only difference is using different fluoro-aromatic ring as starting materials.

2.3 Chemical Synthesis of AG10 Analog 1

Figure.2.1: Synthesis of AG10 Analog 1. A) Methyl-2-fluoro-5-hydroxybenzoate, 4-(3-bromopropyl)-3,5dimethyl-1H-pyrazole, K2CO3, DMF, room temperature, 18-20 hrs; B) NaOH, water, MeOH, 50̊ C reflux,
14 hrs.
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Methyl 5-(3-bromopropoxy)-2-fluoro-benzoate (2): the synthesis scheme of AG10 Analog 1 is
depicted in (Fig. 2.1). To a solution of methyl 2-fluoro-5-hydroxybenzoate 1 (50 mg, 0.59 mmol,
1 equiv) and 4-(3-bromopropyl)-3,5-di-methyl-1H-pyrazole (87 mg) in DMF (2 mL) was added
K2CO3 (101 mg, 1.42 mmol, 2.5 equiv). The reaction mixture was stirred at room temperature
(r.t.) for 16 hrs. The mixture was diluted with EtOAc (1.5 L), washed with brine (3x0.5 L) and
dried with Na2SO4. The solution was filtered and concentrated. The residue was purified by flash
column chromatography (silica gel, 1-10 % EtOAc/hexanes) to afford compound 2 (77 mg, 82 %
yield).
5-[23]-2-fluoro-benzoic acid (AG10 analog 1); to a suspension of 2 (77 mg, 0.33 mmol, 1
equiv) in a mixture of MeOH (1.5 mL) and water (500 µL), NaOH.H2O (21 mg, 0.50 mmol, 2
equiv) was added. The reaction mixture was stirred at 50̊C reflux for 14 hrs. The mixture was
extracted with EtOAc (3 x 30 mL) and the combined organic extracts were dried over anhydrous
sodium sulfate and concentrated in vacuum. The crude product was subjected to flash column
chromatography (silica gel, 10-50 % MeOH/CH2Cl2) to give of AG10 analog 1 (40 mg, 71%
yield) as a white solid (>98 % purity by HPLC).
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Figure.2.2. MS Data showing AG10 Analog 1 (M.WT: 292).

Figure 2.3: HPLC trace of AG10 Analog 1 (>98% purity).
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2.4 Chemical Synthesis of AG10 Analog 2

The synthesis scheme of AG10 Analog 2 is depicted in Figures 2.4.

3

4

AG10 Analog 2

Figur.2.4: Synthesis of AG10 Analog 2. A) Methyl-3-fluoro-5-hydroxybenzoate 4-(3-bromopropyl)-3,5dimethyl-1H-pyrazole, K2CO3, DMF, rt, 18-20 hrs; B) NaOH, water, 50̊ C reflux, 14 hrs.

methyl 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-fluoro-benzoate (4). To a solution of
methyl 4-fluoro-3-hydroxybenzoate 3 (101mg, 0.59 mmol, 2.5 equiv) and 4-(3-bromopropyl)-3,5di-methyl-1H-pyrazole (87 mg) in DMF (2 mL) was added K2CO3 (101mg, 1.42 mmol, 2.5
equiv). The reaction mixture was stirred at room temperature (r.t.) for 16 hrs. The mixture was
diluted with EtOAc (1.5 L), washed with brine (3x0.5 L) and dried with Na2SO4. The solution
was filtered and concentrated. The residue was purified by flash column chromatography (silica
gel, 1-10 % EtOAc/hexanes) to afford compound 4 (4.21 g, 82 % yield).
3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid (AG10 analog 2). To a
suspension of 4 (121.25 mg, 0.40 mmol, 1 equiv) in a mixture of MeOH (1.5 mL) and water
(500µL), NaOH.H2O (33.24 mg, 0.50 mmol, 2 equiv) was added. The reaction mixture was
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stirred at 50̊C reflux for 14 hrs. The mixture was extracted with EtOAc (3 x 30 mL) and the
combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo.
The crude product was subjected to flash column chromatography (silica gel, 10-50 %
MeOH/CH2Cl2) to give of AG10 analog 2 (85 mg, 71% yield) as a white solid (>98 % purity by
HPLC).

Figure.2.5: MS Data showing AG10 Analog 2 (M.WT: 292).
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Figure 2.6: HPLC trace of AG10 Analog 2 (>98% purity).

2.5 Fluorescence Polarization (FP) Binding Assay
Determination of FP Probe Displacement by TTR Ligands. The affinity of test compounds to
TTR was determined by their ability to displace FP probe form TTR using our recently developed
assay [25]. The apparent binding constant was reported as the mean for triplicate experiments and
the best data fit was determined by R2 value.
Determination of IC50 using the FP assay; Serial dilutions of AG10 analogs and tafamidis (40
M to 0.003 M) were added to a solution of FP-probe and TTR in assay buffer (25 L final
volume). The FP assay was then carried out as described above.

2.6. Serum TTR selectivity Assay
The binding affinity and selectivity of the compounds to TTR was determined by their
ability to compete for covalent probe binding to TTR in human serum as previously reported [26].
An aliquot (98 µL) of human serum (Sigma–Aldrich) was mixed with 1 μL of test compounds
(1.0 mM stock solution in DMSO, final concentration: 10 µM) and 1 μL of probe (0.36 mM stock
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solution in DMSO: final concentration: 3.6 µM). The fluorescence changes (λex = 328 nm, λem =
384 nm) were monitored every 15 min using a microplate spectrophotometer reader (Molecular
Devices SpectraMax M5) for 6 hrs at 25o C.
2.7 Results
2.7.1 Binding affinity of AG10 Analogs to TTR
The binding affinities of the AG10 analogs (Fig. 2) to TTR were evaluated and compared
to AG10 using our established fluorescence polarization (FP) assay [25]. The FP assay is a
competitive assay that allows for the measurement of ligand binding to TTR based on their ability
to displace a fluorescent probe [27] from the TTR T4-binding sites. All test compounds were able
to bind to TTR (purified from human plasma) at 10 µM. AG10 and new AG10 analogs, were
assayed in a multi-point dose-response FP assay (concentration range between 40 and 0.00244
µM). The binding affinity of AG10 to WT-TTR (apparent binding constant, IC50 = 87.39, R2 =
0.996) were approximately same than that of AG10 analogs (IC50 = 99.6 and 94.5, R2 = 0.998
and 0.981) (Fig. 2.7).
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Figure.2.7: Evaluation of AG10 analogs binding to TTR in buffer by FP. Competition of FP-probe
from TTR by increasing concentrations (40 to 0.00244 µM) of AG10 (IC50 = 87, R2= 0.996) and AG10
analogs (IC50 = 99.6 and 94.5, R2 = 0.998 and 0.981). Each point shows the mean ± SD of three replicates.

Table.2.1: IC50 value of compounds in Fluorescence polarization.
Compound Name

IC50 Value (nM)

Kd value (nM)

AG10

87.39

18.01

AG10 Analog 1

99.6

20.53

AG10 Analog 2

94.5

19.48

2.7.2 Binding selectivity of AG10 analogs to TTR in human serum
To stabilize TTR tetramers in FAC and SSA patients, small molecules must selectively
bind to TTR in the presence of more than 4,000 other serum proteins. We examined the
selectivity of AG10 analogs for TTR in human serum employing a ligand competition assay using
a covalent probe (Fig. 2.8) [23]. The covalent Probe binds selectively to TTR in serum and then
covalently modifies K15 residue, creating a fluorescent conjugate. Ligands that bind selectively
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to TTR in serum decrease the binding of probe to TTR, decreasing the fluorescence [27].
However, in addition to selectivity, this assay depends also on the relative affinity of probe and
the test compound for the TTR binding sites, especially the second binding site (given that
generally Kd2 > Kd1). Nevertheless, empirically, the results of the probe competition assay at 3 hr
correlate well with other direct measures of selectivity. The compounds (10 µM) are mixed with
human serum (TTR concentration ~5 µM) in the presence of probe (3.6 µM). AG10 analogs
performed better in this assay in serum (42% probe binding for Analog 1 and 41% probe binding
for Analog 2 after 6 hrs) compared to tafamidis (84% probe binding after 6 hrs) (Fig. 2.8). AG10
was more selective to TTR (12% probe binding after 6 hrs) than the two new analogs.
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Figure.2.8: AG10 Analogs binds selectively to TTR in human serum.Fluorescence change caused by
modification of TTR in human serum by covalent probe monitored for 6 hrs in the presence of probe alone
(black circles) or probe and TTR ligands (colors).
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Table.2.2: Percentage of test compound binding to TTR in human serum using covalent probe assay after 3
hrs.

Test Compound

% Binding to TTR

DMSO

0%

Tafamidis

16%

AG10 Analog 1

71.6%

AG10 Analog 2

72%

AG10

92%

2.8 Discussion
Genetic and pharmacologic data have indicated that kinetic stabilization of tetrameric
TTR can slow down disease onset and/or progression [28, 29, 21]. Ligands that bind tightly to the
T4 binding site of TTR reduce tetramer dissociation and subsequent amyloidogenesis. The
selectivity, affinity and efficacy of TTR stabilizers could be optimized if a compound were able
to bind to both the inner cavity and the periphery of the T 4 binding site. This would be especially
critical for compounds aimed at stabilization of disease-associated TTR variants. Using AG10 as
the starting point, we designed two new analogs by changing the position of fluorine atom
[Figure.2]. We hypothesized that the fluorine atom might have an important role in the binding of
AG10 analogs to TTR, because the halogen of the AG10 fits in the halogen binding pocket (HBP)
when AG10 occupies the T4 binding pocket of TTR. Guided by structural information on TTR
ligands [25], we designed and synthesized two AG10 analogs and tested them for affinity,
selectivity, and stabilization of TTR. Among all the analogs, AG10 was the most potent
compound [3]. The new Analogs 1 and 2 displayed higher binding affinity and selectivity to TTR
than tafamidis. However, AG10 was more selective TTR binder than the new analogs.

2.9 Conclusion
The affinity and selectivity of AG10 and newly synthesized AG10 analogs to TTR in
human serum exceeds that of the FAP drug, tafamidis. The binding selectivity and affinity of
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AG10 was much better when compared to AG10 analogs, but still AG10 analogs showed a much
better affinity and selectivity when compared with tafamidis. The new AG10 analogues will be a
starting point for further evaluation. Understanding the reason behind the higher potency of AG10
compared to these analogs would be beneficial for designing stabilizers for other amyloid
diseases.
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Chapter3. Optimization of the structure of TTR ligands for half-life extension
(TLHE) of Therapeutic Peptides

3.1 Introduction
3.1.1 Peptides. Peptides are small chain of amino acids connected by a peptide bond. Distinguished from
proteins based on size, peptides have approximately 50 or less amino acids [30]. They are synthesized by
simple solid phase peptide synthesis where a covalent bond is formed when a carboxyl group of the Cterminal from one amino acid reacts with amine group of the N-terminal from another amino acid, in
peptides the shortest peptide is known as a dipeptide and longest one know as a polypeptide. Therapeutic
peptides are often used in treating a wide range of disorders, such as cancers, diabetes etc [24, 31]. Their
high selectivity, potency, and safety compared with small molecules, make peptides attractive drug
candidates.
Limitations to Use Peptides
Most peptides have short in vivo half-life (2–30 min) owing to enzymatic degradation by
proteases and fast renal clearance (molecules <30 kDa are excreted rapidly by glomerular filtration).
Therefore, extending the in vivo half-life of peptides is clearly desirable for their therapeutic potential to
be realized without the need for high doses and frequent administration.
Strategies to Enhance the Half-life of peptides and their Limitations
There are various methods in the market for increasing the half-life of peptides, the most
commonly used strategies are as follows [32]:
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PEGylation
This method is most commonly used for enhancing the half-life of peptides, where a
native peptide is modified by conjugation to a polyethylene glycol (PEG) [33]. The peptide which
was conjugated to the PEG acquires the molecular size of the PEG, escapes excretion by
glomerular filtration, and escapes the sensitivity of the proteases from degrading which helps in
increasing blood circulation half-life of the peptides.
Limitations of PEGylation
They are a number of drawbacks for PEGylation. For example, PEG is nonbiodegradable and repeated administration of these PEGylated peptides accumulates the PEG in
kidneys and choroid plexus. The PEG generates anti-PEG antibodies [33] which increases the
clearance of PEGylated peptides from the body.
Fusion Protein
Fusion proteins are created when two or more genes originally coded for different
proteins are translated into a single or multiple polypeptides, whose function is derived from the
original protein. In this case, a peptide is genetically fused with human serum albumin (HAS; 67
kDa) [34] to increase the circulation half-life of the peptides.
Limitations of Fusion Protein
The most common problems for this approach are that it has lower affinity towards its
target receptor, shows long terms immunological toxicities [34] and has stability issues for storing
and transporting.
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Lipidation
Lipidation is a process where a hydrophobic fatty acids are conjugated to the peptide of
interest [35, 36]. This results in increasing the circulation half-life of the peptides by allowing it
to bind to human serum albumin.
Limitations of Lipidation
The most common limitations for this method are that it shows lower binding towards its
receptors [35, 36], has some stability issues which make storage and transportation difficult.

3.2 Conjugation to Transthyretin Ligands
Transthyretin is a 55 kDa homo-tetramer, liver secrets transthyretin into blood, choroid
plexus secrets transthyretin in CSF (hTTR concentration in serum is ~ 5 µM) [37] and has in vivo
half-life of 48 hrs. The primary function of hTTR in human is to transport holo-retinol binding
protein and secondary function is to transport T4 binding protein in blood. The Apo-retinol
binding protein which has low binding affinity for hTTR due to the relative small size (21 kDa)
undergoes fast renal excretion having half-life of 3 hrs [37]. The reversible association between
the holo-retinol binding protein and hTTR in blood prevents the glomerular filtration of holoretinol binding protein which results in enhances the circulation half-life (11 hrs). Based on this
natural observation, our laboratory previously demonstrated that conjugation of peptides to a
selective hTTR-binding ligands will help the peptide conjugate to bind reversibly to hTTR and
helps in increasing the in vivo half-life of therapeutic peptides (Figure.3.1). Due to their eversible
binding to hTTR, the intrinsic activity of the peptide conjugates are not adversely affected [38].
Our laboratory developed a potent and selective small molecule hTTR ligand (AG10). At
10 µM, almost all of AG10 was bound to hTTR in human serum [3, 39]. Our lab also successfully
developed several AG10-linker modified analogs (TLHEs) which are used for half-life extension
[39].
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3.3 Our Approach
A major limitation for the above strategies to enhance the half-life of peptides is that the
steric hindrance of macromolecules often harms the binding affinity of peptides to its extracellular receptors, which undermine the therapeutic potency of peptides. Our approach of using
TTR ligand for half-life extension (TLHE <500 Da) should not affect the binding affinity of
peptides to its extra-cellular receptors (Figure 3.1). TLHE are conjugated to peptides through a
short linker that will give TLHE-peptide conjugate the ability to bind reversibly to T 4 binding
sites of endogenous hTTR [39]. This will increase the in vivo half-life of the peptide by protecting
against protease and by decreasing glomerular filtration. Importantly, due to its reversible binding
to hTTR, the binding affinity of the peptide conjugate to its target receptor would not be
adversely affected.

Figure 3: Current approaches for enhancing the in vivo t1/2 of peptides and our new hTTR based
approach. (a) Most peptides have short in vivo t1/2 (2–30 minutes) due to enzymatic degradation by
proteases and fast renal excretion by glomerular filtration. (b) Covalent conjugation of peptides to
macromolecules such as PEG and HSA enhances the in vivo t1/2 of peptides by sterically protecting the
peptide from proteases and by increasing the hydrodynamic size of the peptide and therefore decreasing its
renal excretion. (c) Conjugation of peptides to TTR ligands for half-life extension (TLHEs) (<500 Da),
through a short linker will form TLHE—peptide conjugates. (d) The TLHE—peptide conjugate can bind
reversibly to the T4 binding sites of endogenous hTTR (shown as ribbon diagram with transparent surface).
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3.4 Development of AG10-Linkers for Conjugating Peptides
Our lab had made slight change by removing the fluorine atom of AG10 and attaching a
short linker resulting in TLHE1 (Figure 3.2). TLHE1 maintained good binding affinity and
selectivity to hTTR [39]. My project involved the synthesis of three new TLHEs (TLHE 2, 3, and
4; Figure 3.3). We found that TLHE1 has the best binding affinity and selectivity for hTTR. For
our approach to work in vivo, TLHE1 and its peptide conjugates should be able to selectively
bind to hTTR in the presence of more than 4,000 other human proteins [39]. The binding
selectivity of the TLHE-linker peptide conjugate to hTTR in human serum was evaluated using a
well-established hTTR serum covalent-probe selectivity assay. The lower performance of TLHE1
compared to AG10 was due to the lower binding affinity of TLHE1 and possibly some binding to
other serum proteins. Nevertheless, the activity of TLHE1 in this assay was better than that of the
clinical candidate, tafamidis. TLHE1 was stable in serum for at least 48 hrs and has very low
cytotoxicity [39]. Therefore, TLHE is a very good candidate for conjugation to peptides.
Our modeling suggested that lowering the size of linker to TLHE1 to of ̴ 20Å should be
sufficient to clear the hTTR T4 binding sites and potentially be functionalized with peptides. To
test our hypothesis we conjugated TLHE1 to three different length linkers. The resulting three
TLHEs (TLHE2, TLHE3, and TLHE4) were conjugated to the endogenous peptides,
gonadotropin-releasing hormone (GnRH; 10 amino acid peptide hormone). All Three conjugates
displayed good binding selectivity for hTTR in human serum.
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TLHE 1

Figure.3.1: Structure of TLHE1

TLHE 2

TLHE 4

TLHE 3

R1= -Glu-His-Trp-Ser-Ty r-Gly -Leu-Arg-Pro-Gly -

Figure.3.2: TLHE-Peptide conjugates with different chain linkers.
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3.5 Methods & Materials
3.5.1 Materials
All the peptides, and linkers are synthesized in lab as reported and their reactions were
carried out under a nitrogen or argon atmosphere and anhydrous conditions, unless noted. The
solvents used were ACS grade purchased from Fisher Scientific, and reagents were purchased
from Aldrich and Acros, and used without further purifications. Reactions were monitored using
thin-layer chromatography (TLC) carried out on 0.2mm POLYGRAM® SIL silica gel plates with
fluorescent indicator UV254 using UV light as a visualizer. For purification normal phase flash
column chromatography was carried out using Davisil® silica gel (100-200 mesh, Fisher
Scientific). High resolution mass spectrometry (HRMS) were used to determine the exact mass of
synthesized conjugates and peptides by JEOL AccuTOF DART using helium as an ionization gas
and polyethylene glycol (PEG) as an external calibrating agent. The human serum was obtained
from Sigma, the probe and AG10 was synthesized as reported in reference [3].
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3.6 Chemical synthesis of TLHE1
The synthesis scheme of TLHE1 is depicted in Figure 3.4 and was synthesized as in reference
[39].

Figure.3.3: Synthesis of TLHE1. A) 1,3-dibromopropane, K2CO3, DMF, room temperature, 16 hrs; B)
Acetylacetone, 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), benzene, room temperature, 3 days; C)
hydrazine hydrate, ethanol, 90oC, 4 hrs; D) NaOH, THF, water, room temperature, 14 hrs [39].Methyl 3-
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hydroxy-5-pent-4-ynoxy-benzoate. To a solution of methyl 3, 5-dihydroxybenzoate (5) (6.60 g,
38.93 mmol, 1 equiv) and pent-4-ynyl-4-methylbenzene sulfonate (9.27g, 88.2 mmol, 5 equiv) in
Acetonitrile (60 mL) was added K2CO3 (2.59 g, 16.6 mmol, 2.2 equiv) and KI (311mg, 22 equiv).
The reaction mixture was stirred at room temperature (r.t.) for 16 hrs. The mixture was diluted
with EtOAc (1.5 L), washed with brine (3x0.5 L) and dried with Na2SO4. The solution was
filtered and concentrated. The residue was purified by flash column chromatography (silica gel,
1-60 % hexane/DCM) to afford compound (4 g, 82 % yield); to the above dried compound add
6N HCL (2mL) and THF (2.0mL) and put it under reflux of 50°C for 3.5 hrs then washed with
250mL water and 500mL EtOAC and collect EtOAC mixture, dry to form compound 6.
Methyl 5-[5-hydroxy-4-(1-hydroxyethyl)hexoxy]-2-pent-4-ynoxy-benzoate (7). To a solution
of methyl 5-hydroxy-2-pent-4-ynoxy-benzoate (6) (2.92 g, 3.6 mmol, 1 equiv) and 1,3dibromopropane (6.67 mL, 18.2 mmol, 5 equiv) in DMF (40 mL) was added K 2CO3 (2.08 g, 4.36
mmol, 2.4 equiv). The reaction mixture was stirred at room temperature (r.t.) for 16 hrs. The
mixture was diluted with EtOAc (1.5 L), washed with brine (3x0.5 L) and dried with Na2SO4. A
solution of (7) (840 mg, 2.36 mmol, 1 equiv) in benzene (2 mL) was added dropwise to a
solution of acetyl acetone (1.79 mL, 4.73 mmol, 2 equiv) and DBU (2.638 mL, 4.73 mmol, 2
equiv) in benzene (28 mL). The reaction mixture was stirred at r.t. for 3 days. The mixture was
filtered and concentrated. The residue was purified by flash column chromatography (silica gel,
1-10 % EtOAc/hexanes) to afford compound (8) which was used in the next step directly.
Hydrazine hydrate (456 mL, 6.73 mmol, 2.5 equiv) was added to a solution (8) in ethanol (15
mL) and the reaction was heated under reflux for 4 hrs. The reaction was concentrated and
purified by flash column chromatography (silica gel, 1-20 % MeOH/CH2Cl2) to afford compound
(9) (288 mg, 35% yield) in two steps;
3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-pent-4-ynoxy-benzoic acid (TLHE1). To a
suspension of (9) (100 mg, 0.0946 mmol, 1 equiv) in a mixture of NaOH.H2O (11.89 mg, 0.189
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mmol, 2 equiv) was added to the MeOH (4mL). The reaction mixture was stirred under reflx of
50°C for 12 h after which it was cooled to room temperature. The mixture was fractionated with
EtOAc and MeOH at different concentrations and finally run a thin layer chromatography after
conforming the fraction with compound dry the fraction. The crude product was subjected to
flash column chromatography (silica gel, 10-50% MeOH/CH2Cl2) to give of TLHE1 (30 mg,
32% yield) as a white solid (95% purity by HPLC)
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3.7 Chemical synthesis of GnRH analog 1 (TLHE2-GnRH)

Figure.3.4: Synthesis of TLHE2-GnRH. Reagents and conditions: a) Rink amide resin, DIPEA, DCM, 16
hrs; b) Fmoc SPPS (all L-amino acids); c) Linker, HATU, HOBt, DIPEA, DMF, 24 hrs; d) TLHE1, Cu,
sodium ascorbate, DMF/piperidine (4:1), 16 hrs; e) TFA, phenol, H2O, and TIS (88:5:5:2 ratio) 3 hrs.
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Synthesis of GnRH
The GnRH Peptide was synthesized using standard solid phase synthesis utilizing
Fmoc/tBu protocols. All amino acids used for synthesis are L-Amino acids. The synthesis was
carried out on a rink amide MBHA resin (NovobioChem #855003, 0.79 mmol/g). For the resin
loading step, the resin (250mg, 0.1975 mmol) was reacted with Fmoc-Gly-OH () in DMF (3mL)
and DIC (0.137 mL, 0.875 mmol). The reaction mixture was shaken for 5hrs, the peptides were
built by coupling Fmoc protected (L) amino acid monomers to the first amino-acid attached to the
rink amide resin using DIC, HOBT, in DMF and shaken for 2hrs. Once the GnRH deca-peptide
synthesis was completed, it was dried and used for conjugating the linker.
Synthesis of GnRH-Linker
The azide PEG-linker 3[2-[2-(2- azidoethoxy)ethoxy]ethoxy] proponoic acid was used
directly after synthesis from 3[2-[2-(2-Hydroxyethoxy)ethoxy]ethoxy]propanoic acid tert-butyl
ester taken with Triethylene glycol (104.45 g) with THF (40mL). Then NaOH (5.581 g) mixed
with deionized water (30 mL) are added to the round bottom flask at 0°C, the reaction mixture
was stirred for 15 min. PTScl dissolved in THF (100mL) was added dropwise and stirred for 2hrs
at 0°C. The reaction mixture was washed with water/EtOAc in a separation flask. The EtOAc was
collected concentrated, flash column was done using MeOH/DCM (50:50) which formed purified
(2-[2-(2-hydroxysulphonylethoxy) ethoxy] ethanol). The product was further synthesized by
mixing in DMF (30mL) under nitrogen. Sodium Azide is added and refluxed for half-hour. Then
200mL of water was added to the reaction and (50mL) of EtOAc was added multiple time to
extract compound it was concentrated and purified using a flash column to separate pure
compound. Ethanol, 2-[2-(2-azidoethoxy)ethoxy] (200mg) was further dissolved with acetone
(12mL) and kept at 0°C, Chromium oxide (521.1mg) in 1.5m of sulfuric acid (6mL) was slowly
added at 0°C, then the reaction is slowly changed to room temperature for overnight. Finally
isopropanol was added to quench the reaction. The final compound (2-[2-(2- azidoethoxy)
ethoxy] acetic acid) is dried and stored.
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The GnRH peptide-linker was synthesized in a similar way to what described above for
GnRH synthesis. The only difference is that we used glutamic acid instead of pyro-glutamic acid
the N-terminus. The azide PEG linker (37.5 mg, 0.198 mmol) is activated in HATU (150.6 mg,
0.396 mmol), HOBT (53.58 mg, 0.396 mmol), DIPEA (51.2 mg, 0.396 mmol) and DMF (3mL).
All the reagents are added to the GnRH peptide before the product was cleaved from the resin, the
reaction mixture was shaken for 20 hrs.
Synthesis of TLHE2-GnRH
The click reaction was carried out by the resin bound GnRH-linker (0.132 mmole), 3-[3(3, 5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-pent-4-ynoxy-benzoic acid (34 mg, 0.132mmol),
copper iodide (75mg, 0.132mmol), Sodium ascorbate (78.4 mg, 0.132mmol), DMF/piperidine
(4:1) 3mL, the mixture was transferred into the reaction flask under nitrogen gas and reaction was
left for 16 hrs in room temperature. The product was then cleaved from the resin including the
deprotonation of groups present in the side chains groups was performed by treating with
cleavage cocktail which contains TFA, phenol, water, and TIS (88:5:5:2) ratio, shaken with this
cocktail for 1 to 1 ½hr. After cleavage the resulting product was collected in cold ether and
washed multiple times with ether and finally centrifuged to separate the GnRH peptide-linkerconjugate in the form of precipitate, the precipitate was dried and purified using preparative
HPLC using (50:50) of buffer for injecting the peptide conjugate using buffer solvent A and B
(buffer A: water, methanol, TFA at ratio 95:5:0.1) and (buffer B: methanol, water, TFA at ratio
95:5:0.1) using C18 column.
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Figure 3.5: MS data showing TLHE2-GnRH (M.Wt: 1787.5).

Figure 3.6: HPLC trace of TLHE2-GnRH (>98 % purity).
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3.8 Chemical synthesis of GnRH analog 2 (TLHE3-GnRH)

Figure.3.7: Synthesis of TLHE3-GnRH. Reagents and conditions: a) Rink amide resin, DIPEA, DCM, 16
h; b) Fmoc SPPS (all L-amino acids); c) Linker, HATU, HOBt, DIPEA, DMF, 24 h; d) TLHE1, CuI,
sodium ascorbate, DMF/piperidine (4:1), 16 h; e) TFA, phenol, H2O, and TIS (88:5:5:2 ratio) 3h.
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Chemical Synthesis of GnRH
The synthesis of the peptide is same as previously explained in (3.7)
Synthesis of GnRH-Linker
The azide PEG-linker (2-[2-(2- azidoethoxy) ethoxy] acetic acid) was used directly after
synthesis from (2-[2-(2-hydroxyethoxy) ethoxy] ethanol) taken with T-glycol (104.45 g) with
THF (40mL). Then NaOH (5.581 g) mixed with deionized water (30 mL) was slowly added to a
round bottom flask at 0°C, the reaction mixture was stirred for 15 minutes. PTScl dissolved in
THF (100mL) was added dropwise and stirred for 2hrs at 0°C. The reaction mixture was washed
with water/EtOAc in a separation flask, The EtOAc was collected concentrated, and flash column
was

done

using

MeOH/DCM

(50:50)

and

which

formed

purified

(2-[2-(2-

hydroxysulphonylethoxy) ethoxy] ethanol). The product was further synthesized by mixing in
DMF (30mL) under nitrogen Sodium azide was added and refluxed for half-hour, then 200mL of
water was added to the reaction and (50mL) of EtOAc was added multiple time to extract
compound it was concentrated and purified using a flash column to separate pure compound.
Ethanol, 2-[2-(2-azidoethoxy)ethoxy] (200mg) was then dissolved with acetone (12mL) and kept
at 0°C, chromium oxide (521.1mg) in 1.5M sulfuric acid (6mL) was slowly added at 0°C. The
reaction then gradually changed to room temperature for overnight. Finally isopropanol was
added to quench the reaction. The final compound (2-[2-(2- azidoethoxy) ethoxy] acetic acid) was
dried and stored.
The GnRH peptide- Linker was synthesized in a similar way to what described above for
the GnRH synthesis. The only difference is that we used glutamic acid instead of pyro-glutamic
acid at N-terminus. The azide PEG linker (37.5 mg, 0.198 mmol) is activated in HATU (150.6
mg, 0.396 mmol), HOBT (53.58 mg, 0.396 mmol), DIPEA (51.2 mg, 0.396 mmol) and DMF
(3mL). All the reagents are added to the GnRH peptide before the product was cleaved from the
resin, the reaction mixture was shaken for 20 hrs.
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Synthesis of TLHE3-GnRH
The click reaction was carried out by the resin bound GnRH-linker (0.132 mmole), 3-[3(3, 5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-pent-4-ynoxy-benzoic acid (34 mg, 0.132mmol),
copper iodide (75mg, 0.132mmol), Sodium ascorbate (78.4mg, 0.132mmol), DMF/piperidine
(4:1) 3mL, the mixture was transferred into the reaction flask under nitrogen gas and reaction was
left for 16 hrs in room temperature. The product was then cleaved from the resin including the
deprotonation of groups present in the side chains groups was performed by treating with
cleavage cocktail which contains TFA, phenol, water, and TIS (88:5:5:2) ratio, shaken with this
cocktail for 1 to 1 ½hr. After cleavage the resulting product was collected in cold ether and
washed multiple times with ether and finally centrifuged to separate the GnRH peptide-linkerconjugate in the form of precipitate, the precipitate was dried and purified using preparative
HPLC using (50:50) of buffer for injecting the peptide conjugate using buffer solvent A and B
(buffer A: water, methanol, TFA at ratio 95:5:0.1) and (buffer B: methanol, water, TFA at ratio
95:5:0.1) using C18 column.
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Figure 3.8: MS data showing TLHE3-GnRH (M.Wt: 1728).

Figure 3.9: HPLC trace of TLHE3-GnRH (>99.20 % purity).
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3.9 Chemical synthesis of TLHE4-GnRH

Figure.3.10: Synthesis of TLHE4-GnRH. Reagents and conditions: a) Rink amide resin, DIPEA, DCM,
16 h; b) Fmoc SPPS (all L-amino acids); c) Linker, HATU, HOBt, DIPEA, DMF, 24 h; d) TLHE1, CuI,
sodium ascorbate, DMF/piperidine (4:1), 16 h; e) TFA, phenol, H 2O, and TIS (88:5:5:2 ratio) 3 hrs.
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Synthesis of GnRH
The synthesis of the peptide is same as previously explained in (3.7). Synthesis of GnRHLinker
The azide PEG-linker (5-Azido pentaonic acid) was ordered from Sigma Aldrich (CAS
Number 79583-98-5), and The GnRH peptide- Linker is synthesized in a similar way to what
described above for GnRH synthesis, the only difference was here we are using glutamic acid
instead of pyro-glutamic acid at N-terminus. The azide PEG linker (27.91mg, 0.065 mmol) is
activated in HATU (74.14mg, 0.065 mmol), HOBT (29.86 mg, 0.065 mmol), DIPEA (16.79 mg,
0.065 mmol) and DMF (3mL). All the reagents are added to the GnRH peptide before the product
was cleaved from the resin, the reaction mixture was shaken for 20 hrs.
Synthesis of TLHE4-GnRH
The click reaction was carried out by the resin bound GnRH-linker (0.132 mmole), 3-[3(3, 5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-pent-4-ynoxy-benzoic acid (34 mg, 0.132mmol),
copper iodide (75mg, 0.132mmol), Sodium ascorbate (78.4mg, 0.132mmol), DMF/piperidine
(4:1) 3mL, the mixture was transferred into the reaction flask under nitrogen gas and reaction was
left for 16 hrs in room temperature. The product was then cleaved from the resin including the
deprotonation of groups present in the side chains groups was performed by treating with
cleavage cocktail which contains TFA, phenol, water, and TIS (88:5:5:2) ratio, shaken with this
cocktail for 1 to 1 ½hr. After cleavage the resulting product was collected in cold ether and
washed multiple times with ether and finally centrifuged to separate the GnRH peptide-linkerconjugate in the form of precipitate, the precipitate was dried and purified using preparative
HPLC using (50:50) of buffer for injecting the peptide conjugate using buffer solvent A and B
(buffer A: water, methanol, TFA at ratio 95:5:0.1) and (buffer B: methanol, water, TFA at ratio
95:5:0.1) using C18 column.
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Figure 3.11: MS data showing TLHE4-GnRH (M.Wt: 1682.4).

Figure 3.12: HPLC trace of TLHE4-GnRH (>97 % purity).
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3.10 Results
3.11 TLHE-GnRH Conjugates Bind Selectively to WT-TTR in Human Serum
The selectivity of TLHE-GnRH conjugates to hTTR in human serum was evaluated using
a well-established hTTR serum covalent-probe selectively assay [3, 39, 23] as shown in
(Fig.3.14) The lower performance of TLHE-Peptide analogs TLHE2-GnRH, TLHE3-GnRH,
and TLHE4-GnRH (47%, 46%, and 36% binding to hTTR in serum) compared to AG10 (Kd =
13.8 nM; 87% binding to hTTR in serum) was due to the lower binding affinity of conjugates to
hTTR and possibly some binding to other serum proteins. However, the binding affinity and
selectivity of TLHE-GnRH conjugated in this assay were better than that of the clinical candidate,
tafamidis (16% binding to hTTR in serum).
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Figure.3.13: Fluorescence change caused by covalent probe (hTTR concentration, ~5 μM) by covalent
probe monitored for 6 h in the presence of covalent probe alone (black circles) or covalent probe and
GnRH attached hTTR ligands (colors; 10 μM). The lower the binding and fluorescence of covalent probe,
the higher binding selectivity of ligand to hTTR. Each bar shows the mean ± SD of three replicates.
Table.3.1: Showing the percentage of TLHE-GnRH binding to hTTR in human serum using covalent
probe Assay after (3 hrs).
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Compound Name

% Binding to TTR

DMSO

11%

Tafamidis

30%

TLHE2-GnRH

61%

TLHE4-GnRH
TLHE3-GnRH

67%
69%

AG10

94%

3.12 hTTR Protected TLHE-GnRH Conjugates against Serum Protease
We tested the ability of hTTR to protect TLHE-GnRH conjugates against proteolytic
hydrolysis in human serum. The stability of the conjugates was evaluated in human serum (hTTR
conc. ~5 µM). It was determined that the GnRH peptide had the lowest stability in serum (no
amount detected after 8 hrs). Attaching three different linkers to GnRH (GnRH-linker) enhanced
their stability. However they still are considered small molecules which are rapidly excreted by
the kidneys. Therefore, we conjugated linker-GnRH to the TLHEs which has a good binding
affinity with TTR, to see whether it protects the peptide from protease and glomerular filtration
by increasing the molecule’s size. After performing the serum protease stability assay we found
that the stability of the conjugates was enhanced and GnRH-conjugates were protected against
serum protease degradation in comparison to GnRH (Fig.3.15 and Table- 3.2).
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Figure.3.14: hTTR protected TLHE4-GnRH 62%, TLHE2-GnRH 38%, and TLHE3-GnRH 36%,
against proteolytic hydrolysis in human serum. Test compounds (5 μM) were added to serum and to serum.
The amounts of compounds remaining in serum were quantitated at indicated time points. Each point
shows the mean ± SD of three replicate.

Table 3.2: Showing the percentage of the THLE-GnRH conjugates remaining in human serum
after 48 hrs of incubation.
Compound Name

% Remaining in serum after 48
hrs

GnRH

0%

TLHE2-GnRH

38%

TLHE3-GnRH

36%

TLHE4-GnRH

62%
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3.13 Binding affinity of TLHE-GnRH conjugates to TTR
The binding affinity of TLHE-GnRH conjugates to TTR at physiological pH was
evaluated using our established fluorescence polarization (FP) assay [25]. The FP assay is a
competitive assay that allows measurement of ligand binding to TTR based on their ability to
displace a fluorescent probe [27] from the TTR T4-binding sites. All test compounds were able to
bind to TTR (purified from human plasma) at 10 µM. The TLHE-GnRH conjugates and AG10
were then assayed in a multi-point dose-response FP assay (concentration range between 40 and
0.02 µM). The binding affinity of AG10 to TTR (apparent binding constant, IC50 = 85.36 nM, R2
= 0.991) was better than the GnRH- analogs and TLHE ligands. The binding affinity of TLHE1
and to TTR (TLHE1; IC50 = 204.3 nM, R2 = 0.9905). The binding affinity of GnRH- analogs to
WT-TTR were as follows: TLHE2-GnRH (IC50 = 1047.64 nM, R2=0.99); TLHE3-GnRH (IC50 =
1370.16 nM, R2=0.98); TLHE4-GnRH (IC50 = 1505 nM, R2=0.9815) (Figure.3.16 and table
3.16.1).

F lu o r e s c e n c e P o la r iz a tio n

% P o la r iz a tio n

100

T L H E 2 -G n R H
T L H E 3 -G n R H
T L H E 4 -G n R H

50

T L H E 1 -G n R H
A G 10

0
1 .4

2 .2 1 8 8 5 1

3 .5 1 6 6 4 1

lo g [n M ]

Figure.3.15: Evaluation of ligand binding to TTR in buffer by FP. Competition of FP-probe from TTR
by increasing concentrations (40 and 0.02 µM) of TLHE-GnRH conjugates: TLHE3-GnRH (IC50 = 1047.64
nM, R2=0.99); TLHE2-GnRH (IC50 = 1370.16 nM, R2=0.98); TLHE4-GnRH (IC50 = 1505 nM, R2=0.9815).
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Each point shows the mean ± SD of three replicates. Table.3.3: IC50 value for binding affinity of TLHEGnRH conjugates to TTR using Fluorescence polarization
Compound Name

IC50 (nM) Value

Kd (nM)Value

AG10

85.36

17.6

TLHE1

90

18.55

TLHE2-GnRH

1370.64

285.45

TLHE3-GnRH

1047.16

234.2

TLHE4-GnRH

1505.28

310.30

.

3.14 Discussion
There are various attractive technologies like conjugation to PEG and albumins for large
peptides and proteins, which enhance the half-life of peptides. However; these strategies have
some limitations, such as non-biodegradability, immunogenicity and low binding affinity with the
target receptors because of the steric hindrance. Therefore, the TLHE1 system has the potential to
optimize half-life extension of peptides without affecting the binding with their receptors. In
addition, our approach offers a number of additional advantages over other strategies. Our
technology involves a simple chemical conjugation of the peptide to TLHE1, and the products are
homogenous, easily characterized and purified in harsh conditions like HPLC.
GnRH agonist is a ten amino acid peptide used to treat prostate and breast cancers, as
well as fertility disorders yet it has a small half-life. Our THLE technology increased the half-life
of GnRH-analogs by improving their binding affinity and selectivity to hTTR.

3.15 Conclusion
Conjugation of peptides and proteins to PEG and albumin are considered as an attractive
technology, But the TLHE system has additional advantages for enhancing the half-life of
peptides. Besides maintaining the potency, our technology provides a number of advantages over
traditional genetic fusion, PEGylation and human serum albumin conjugations. Our approach
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involves in a simple chemical conjugation of peptides, linkers and TLHEs, and the products are
homogenous and can be easily purified and characterized using harsh conditions such as HPLC.
The nature of synthesis offers flexibility of attachment sites and incorporates the unnatural amino
acids or non-peptidic functionality into the peptide. Unlike HSA peptide conjugation, where the
three-dimensional structure of the fusion partner need to be maintained, but conjugation to
TLHEs results in stable product that do not need refrigeration, which decreases the cost of
production, transportation and storage. Because of the small size we anticipate our conjugates
penetrate solid tumors efficiently. Due to non-peptidic nature and small size, it is unlikely that
TLHEs will cause any immunogenic response.
From the preliminary screening of the synthesized TLHE-GnRH conjugates, we can
conclude that lowering the linker length provide better selectivity and protection against serum
protease cleavage.
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